(Q38337206)

English

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

0 references

Victor A. Gault

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Barry D Kerr

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Patrick Harriott

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

0 references

publication date

1 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Clinical Science

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

121

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

107-117

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Diabetes: Strategies to prevent the type 2 diabetes mellitus epidemic

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Peptides and the control of meal size

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

The role of GLP-1 in neuronal activity and neurodegeneration

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Neuroprotective properties of GLP-1: theoretical and practical applications

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

The incretin system and its role in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

1 reference

https://api.crossref.org/works/10.1042%2FCS20110006

21 January 2018

Identifiers

10.1042/CS20110006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332446%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38337206&oldid=1509543806"